Jupiter Neurosciences, Inc. (JUNS) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol formulation for CNS disorders (currently targeting Parkinson's disease), and a consumer supplement line called Nugevia. The company operates as a non-accelerated filer and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Product Revenue | $18,652 | $0 |
| Gross Profit | $14,290 | $0 |
| Net Loss | $(2,061,958) | $(1,528,867) |
| Net Loss Per Share (Basic/Diluted) | $(0.06) | $(0.05) |
| Cash and Cash Equivalents (End of Period) | $2,362,749 | $2,706,469 |
| Net Cash Used in Operating Activities | $(1,432,100) | $(1,063,041) |
| Convertible Notes Payable (Fair Value) | $4,824,411 | $5,298,068 |
| Accumulated Deficit | $(36,728,984) | $(34,667,026) |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded its first product revenue of $18,652 in Q1 2026 from the Nugevia supplement line, compared to zero in the prior year.
- Expense Growth: General and Administrative (G&A) expenses increased by 46% to $1.57 million, driven by payroll, Nugevia launch costs, and investor relations. Research and Development (R&D) expenses decreased by 12% to $411,049.
- Interest Expense: Interest expense surged to $118,644 (from $1,229) due to the issuance of convertible promissory notes under a Standby Equity Purchase Agreement (SEPA) in late 2025.
- Liquidity: Cash balances decreased by approximately $1.43 million during the quarter due to operating losses.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded that conditions raise substantial doubt about the company's ability to continue as a going concern for at least twelve months. The auditor has included an explanatory paragraph regarding this risk.
- Capital Requirements: The company requires substantial additional capital to fund operations and clinical trials. It relies on the SEPA with Yorkville (up to $20 million) and equity sales to service debt and fund operations.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq minimum bid price ($1.00) and market value of listed securities ($35 million) requirements. It has until August 25, 2026, to regain compliance.
- Clinical Pipeline: A Phase IIa clinical trial for Parkinson's disease received FDA IND approval in November 2025 and is expected to commence in Q2 2026.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding the segregation of duties in financial transaction processing.
Investor Verification Checklist
- Cash Runway: Verify if current cash ($2.36M) is sufficient to cover the upcoming Phase IIa trial costs and debt service obligations given the burn rate of ~$1.4M/quarter.
- Debt Structure: Review the terms of the Convertible Notes (8% interest, 18% on default) and the requirement to repay 1/10th of principal monthly starting April 1, 2026.
- Nasdaq Status: Monitor stock price performance to ensure compliance with the $1.00 minimum bid price requirement by the August 2026 deadline.
- Revenue Sustainability: Assess whether Nugevia revenue ($18k) can scale to meaningfully offset operating losses or if it remains negligible relative to R&D spend.
- Dilution Risk: Evaluate the potential for significant shareholder dilution as the company utilizes the SEPA and issues stock to pay interest and principal on convertible notes.